EfficientIn VivoGene Transfer into the Heart in the Rat Myocardial Infarction Model Using the HVJ (Hemagglutinating Virus of Japan)—Liposome Method

The lack of efficient treatment for myocardial infarction remains an unresolved problem in the field of cardiovascular disease. Gene therapy may be a potential therapeutic strategy for the treatment of myocardial infarction. However, current methods ofin vivogene transfer into the heart are limited by their low efficiency and/or potential toxicity. In the present study, we developed an efficient technique of gene transfer into the intact heartin vivousing the Sendai virus (HVJ: Hemagglutinating Virus of Japan)—liposome method. We used theβ-galactosidase gene, luciferase gene and human angiotensin converting enzyme (ACE) gene as markers.In vivogene transfer into the rat heart was performed as follows: (1) direct injection into the rat heart, (2) incubation within the pericardium, and (3) infusion into a coronary artery. Direct injection of the HVJ–liposome complex containing theβ-galactosidase vector into the rat heart resulted in limited staining ofβ-galactosidase 3 days after transfection. To compare transfection efficiency between “naked” plasmid DNA transfection and the HVJ–liposome method, we also transfected the luciferase reporter gene into the heart. Luciferase activity was significantly higher in hearts transfected by the HVJ–liposome method than that in hearts transfected by direct “naked” plasmid transfection (P<0.01). To confirm the successful gene in the protein level, we measured ACE activity in the hearts. Cardiac ACE activity was significantly increased in hearts transfected with human ACE gene as compared to hearts transfected with control vector (P<0.01). On the other hand, incubation of HVJ–liposome complex, containingβ-galactosidase vector, within the pericardium resulted in widespread staining of cardiac myocytes and fibroblasts, mainly located in several surface layers beneath the pericardium. More importantly, widespread stained areas ofβ-galactosidase were also observed in the middle of the myocardium around the vasa vasorum. We also examined the efficiency of gene transfer by the HVJ–liposome method in a rat myocardial infarction model. In the infarction model, using the pericardium incubation approach, staining forβ-galactosidase was observed in the viable cells around the infarction area. Finally, direct infusion of the HVJ complex, containing theβ-galactosidase vector, into coronary artery also resulted in widespread staining ofβ-galactosidase in cardiac myocytes around the microvasculature. Using direct injection, we found significant injury to the myocardium and severe fibrosis at the injection site, whereas no apparent injury was observed using pericardium incubation and coronary infusion. There was no evidence of cytotoxicity or inflammation caused by the HVJ–liposome complex itself. Overall, we have established an efficientin vivogene transfer method into the heart using the HVJ–liposome method. Direct infusion into the coronary artery resulted in widespread transfection without damaging the myocytes; incubation within the pericardium demonstrated the usefulness of the HVJ–liposome method for studying cardiac function and as a means of gene therapy for cardiovascular diseases.